Filtros de búsqueda

Lista de obras de

Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.

artículo científico publicado en 2018

Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry disease

artículo científico publicado en 2018

Association between Comorbidities and Progression of Transvalvular Pressure Gradients in Patients with Moderate and Severe Aortic Valve Stenosis

artículo científico publicado en 2018

Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry disease.

artículo científico publicado en 2017

Case report of a 45-year old female Fabry disease patient carrying two alpha-galactosidase A gene mutation alleles.

artículo científico publicado en 2016

Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study

artículo científico publicado en 2016

Characterization of vertigo and hearing loss in patients with Fabry disease

artículo científico publicado en 2018

Clinical impact of the alpha-galactosidase A gene single nucleotide polymorphism -10C>T: A single-center observational study.

artículo científico publicado en 2018

Coronary B-cell lymphoma infiltration causing myocardial infarction

artículo científico publicado en 2020

Die Fabry-Kardiomyopathie als Differenzialdiagnose des akuten Koronarsyndroms

artículo científico publicado en 2017

Echocardiographic Determinants of One-Year All-Cause Mortality in Patients With Chronic Heart Failure Complicated by Significant Functional Tricuspid Regurgitation

artículo científico publicado en 2016

Immunosuppressive effect on ERT inhibition in transplanted patients with Fabry disease

scholarly article by Malte Lenders published in January 2017

Letter by Oder et al Regarding Article, "Early Cardiac Involvement Affects Left Ventricular Longitudinal Function in Females Carrying α-Galactosidase A Mutation: Role of Hybrid Positron Emission Tomography and Magnetic Resonance Imaging and Speckle-

artículo científico publicado en 2018

Long Term Treatment with Enzyme Replacement Therapy in Patients with Fabry Disease

artículo científico publicado en 2016

Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement

artículo científico publicado en 2017

Lucerastat, an iminosugar for substrate reduction therapy: safety, tolerability, pharmacodynamics, and pharmacokinetics in adult subjects with Fabry disease

scholarly article by Nicolas Guérard published in January 2017

Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year

artículo científico publicado en 2019

Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313Y.

artículo científico publicado en 2016

Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors

artículo científico publicado en 2017

Value of cardiac biomarker measurement in the differential diagnosis of infiltrative cardiomyopathy patients with preserved left ventricular systolic function

artículo científico publicado en 2018

Value of the CHA2DS2-VASc score and Fabry-specific score for predicting new-onset or recurrent stroke/TIA in Fabry disease patients without atrial fibrillation

scientific article published on 24 May 2018

α-Galactosidase A Genotype N215S Induces a Specific Cardiac Variant of Fabry Disease

artículo científico publicado en 2017

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda